Related Experiment Video
Updated: Jul 5, 2025
07:41
Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device
Published on: July 20, 2022
1.9K
Extended and Safe Support with the CentriMag® Temporary Ventricular Assist Device Implanted with Skirted-Cannula
Chan-Yang Hsu1, I-Shiang Tzeng2, Jenn-Yeu Song1
1Division of Cardiovascular Surgery, Department of Surgery.
Acta Cardiologica Sinica
|January 24, 2024
Summary
Extended use of the CentriMag ventricular assist device (VAD) beyond 30 days, particularly with the skirted cannula technique, demonstrates acceptable survival rates for patients awaiting recovery or transplantation.
Area of Science:
- Cardiology
- Medical Devices
- Surgical Technology
Background:
- CentriMag® is indicated for temporary circulatory support up to 30 days.
- Extended use beyond this period is common, with variable outcomes.
- Experience with prolonged CentriMag support needs further review.
Purpose of the Study:
- To review the clinical experience with extended CentriMag support.
- To evaluate outcomes of patients requiring circulatory support for over 30 days.
- To assess the safety and efficacy of the skirted cannula technique for CentriMag LVAD implantation.
Main Methods:
- Retrospective analysis of 19 patients supported with CentriMag LVAD.
- Patients received support as a bridge to recovery, VAD, or transplantation.
- Data collected from September 2011 to October 2021.
Main Results:
- 14 out of 19 patients received support for longer than 30 days.
- The overall 1-year survival rate was 73.7%.
- Support duration ranged from 6 to 191 days (median 41 days).
Conclusions:
- The skirted cannula technique for CentriMag LVAD implantation is safe and durable.
- Extended use of CentriMag (over 30 days) is associated with acceptable survival.
- Complications were not common with this technique and duration of support.
